[1] 曹雪涛,何维.医学免疫学[M].北京:人民卫生出版社,2015,26-33.
[2] Abdelsadik A,Trad A.Toll-like receptors on the fork roads between innate and adaptive immunity[J].Hum Immunol,2011,72(12):1188-1193.
[3] Hamidzadeh K,Mosser DM.Purinergic Signaling to TerminateTLRResponses in Macrophages[J].Front Immunol,2016,7(5):74-74.
[4] 于莉莉,韩代书.Toll样受体(TLR)介导的天然免疫间的相互调节[J].中国组织化学与细胞化学杂志,2013,2(1):79-84.
[5] 周敬禹,杨桂连,王春凤.TLR信号途径对于NF-κB活化的调控及作用机制[J].畜牧与兽医,2015,47(1):117-120.
[6] Hamidzadeh K,Mosser DM.Purinergic Signaling to TerminateTLRResponses in Macrophages[J].Front Immunol, 2016,7(1):74-74.
[7] Avbelj M,Horvat S,Jerala R.The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition ofTLRs[J].J Immunol,2011,187(5):2394-2404.
[8] Deng L,Pang P,Zheng K,et al.Forsythoside A Controls Influenza A Virus Infection and Improves the Prognosis by Inhibiting Virus Replication in Mice[J].Molecules,2016,21(5):524-524.
[9] Sender V,Stamme C.Lung cell-specific modulation of LPS-induced TLR4 receptor and adaptor localization[J].Commun Integr Biol,2014,7(4):e29053.
[10] Fukata M,Abreu MT.TLR4 signalling in the intestine in health and disease[J].Biochem Soc Trans,2007,35(6):1473—1478.
[11] Kobayashi K,Hernandez L D,Galan J E,et a1.IRAK-M is a negative regulator of Toll-like receptor signaling[J].Cell,2002,110(2):191-202.
[12] 章烈,李园,周总光.髓样分化因子88的研究进展:把握TLR信号通路中的瓶颈[J].中国普外基础与临床杂志,2013,20(6):685-690.
[13] Hacker H,Redecke V,Blagoev B,et a1.Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6[J].Nature, 2006,439(7073):204—207.
[14] Kajihara H,Yamada Y,Kanayama S,et al.Clear cell carcinoma of the ovary:potential pathogenic mechanisms (Review)[J].Oncol Rep,2010,23(5):1193-1203.
[15] Adhikari A,Xu M,Chen Z J.Ubiquitin—mediated activation of TAKl and IKK[J].Oncogene,2007,26(22):3214-3226.
[16] Peng XQ,Zhou HF,Zhang YY,et al.Antiviral effects of Yinhuapinggan granule against influenza virus infection in the ICR mice model[J].Journal of natural medicines, 2016,70(1):75-88.
[17] Wu H,Arron JR.TRAF6,a molecular bridge spanning adaptive immunity,innate immunity and osteoimmunology[J].Bioessays,2003,25(11):1096-1105.
[18] Ghosh S,Dass JF.Study of pathway cross-talk interactions with NF-κB leading to its activation via ubiquitination or phosphorylation:A brief review[J].Gene,2016,584(1):97-109.
[19] Kawasaki T,Kawai T.Toll-like receptor signaling pathways[J].Front Immunol,2014,5(461):461-461.
[20] 陈华群,张锡然,KimOrth.TRAF6在NF-kappaB信号通路中的修饰与降解[J].南京医科大学学报(自然科学版),2004,24(1):59-62.
[21] landstromM.TheTAK1-TRAF6 signalling pathway[J].Int J Biochem Cell Biol,2010,42(5):585-589.
[22] Kameda H,Watanabe M,Bohqaki M,et al.Inhibition of NF-kappaB signaling via tyrosine phosphorylation of Ymer[J]. Biochem Biophys Res Commun,2009,378(4):744-749.
[23] Gilmore T D.Introduction to NF-kappaB:players,pathways,perspeetives[J].Oncogene,2006,25(51):6680-6684.
[24] Iyre AK,Azad N,Talbot S,et al.Antioxidant c-FLIP inhibits Fas ligand-induced NF-kappaB activation in a phosphatidylinositol 3-kinase/Akt-dependent manner[J].J Immunol,2011,187(6):3256-3266.
[25] Hayden M S,West A P,Ghosh S.NF-KB and the immune response[J].Oncogen,2006,25(51):6758-6780.
[26] Karin M,Greten F R.NF-kappaB:linking inflammation and immunity to cancer development and progression[J].Nat Rev Immunol,2005,5(10):749-759.
[27] Kwon HJ,Choi GE,Ryu S,et al.Stepwise phosphorylation of p65 promotesNF-κB activation and NK cell responses during target cell recognition[J].Nat Commun,2016,7(1):57-71.
[29] Mitchell S,Vargas J,Hoffmann.Signaling via the NFκB system[J].Wiley Interdiscip Rev Syst Biol Med,2016 ,8(3):227-241.
[30] Kalliolias GD,Ivashkiv LB.TNF biology,pathogenic mechanisms and emerging therapeutic strategies[J].Nat Rev Rheumatol,2016,12(1):49-62. |
